Michigan late-stage biopharma, Sling Therapeutics, said a Phase IIb/III LIDS trial of its oral small molecule therapy designed to treat thyroid eye disease (TED) met its primary endpoint.
Thyroid eye disease (TED) therapy Tepezza – the top asset in Amgen's $26 billion takeover of Horizon in 2023 – could be facing competition from an easier-to-dose alternative from Sling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback